Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909972 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Aileron Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 6
- Study locations
NCT02909972: Completed Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Aileron Therapeutics.
NCT02909972 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that has completed, run by Aileron Therapeutics. The registered enrollment target is 55 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02909972, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Aileron Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53
Primary Outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0
Conditions Studied
Interventions
- DRUG ALRN-6924
- DRUG ALRN-6924 in combination with cytarabine
Study Locations (6)
Colorado
- - Denver
Florida
- - Tampa
New York
- - The Bronx
Oregon
- - Portland
South Carolina
- - Greenville
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
What the finished NCT02909972 record still lists
NCT02909972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which ALRN-6924 is the first listed.
NCT02909972 lists 6 locations in 6 states (Colorado, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT02909972 about?
NCT02909972 is a clinical study titled "Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome". Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemi...
What is the current status of trial NCT02909972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2016-09. Estimated completion is 2019-08.
What conditions does trial NCT02909972 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT02909972?
The interventions under investigation include: ALRN-6924 (DRUG), ALRN-6924 in combination with cytarabine (DRUG).
Who is sponsoring clinical trial NCT02909972?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02909972 being conducted?
This trial has 6 study locations across Colorado, Florida, New York, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02909972's enrollment target sits among peer trials
55 132nd of 306 higher than 175 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia